On March 5, 2026, Vistagen Therapeutics, Inc. announced a 20% reduction in its workforce to manage cash flow effectively while focusing on its ongoing clinical studies. They expect to report topline results from the PALISADE-4 Phase 3 trial in early 2026 and anticipate their cash runway will extend into 2027.